BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34003298)

  • 1. Initial Stage of Cutaneous Primary Melanoma Plays a Key Role in the Pattern and Timing of Disease Recurrence.
    Ertekin SS; Podlipnik S; Riquelme-Mc Loughlin C; Barreiro-Capurro A; Arance A; Carrera C; Malvehy J; Puig S
    Acta Derm Venereol; 2021 Jul; 101(7):adv00502. PubMed ID: 34003298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stage-Specific Risk of Recurrence and Death From Melanoma in Denmark, 2008-2021: A National Observational Cohort Study of 25 720 Patients With Stage IA to IV Melanoma.
    Helvind NM; Brinch-Møller Weitemeyer M; Chakera AH; Hendel HW; Ellebæk E; Svane IM; Kjærskov MW; Bojesen S; Skyum H; Petersen SK; Bastholt L; Johansen C; Bidstrup PE; Hölmich LR
    JAMA Dermatol; 2023 Nov; 159(11):1213-1222. PubMed ID: 37650576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrence behavior in early-stage cutaneous melanoma: pattern, timing, survival, and influencing factors.
    Tas F; Erturk K
    Melanoma Res; 2017 Apr; 27(2):134-139. PubMed ID: 28099368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanoma.
    Leeneman B; Franken MG; Coupé VMH; Hendriks MP; Kruit W; Plaisier PW; van Ruth S; Verstijnen JAMC; Wouters MWJM; Blommestein HM; Uyl-de Groot CA
    Eur J Surg Oncol; 2019 May; 45(5):825-831. PubMed ID: 30765270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma.
    Poo-Hwu WJ; Ariyan S; Lamb L; Papac R; Zelterman D; Hu GL; Brown J; Fischer D; Bolognia J; Buzaid AC
    Cancer; 1999 Dec; 86(11):2252-8. PubMed ID: 10590365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma.
    Harcharik S; Bernardo S; Moskalenko M; Pan M; Sivendran M; Bell H; Hall LD; Castillo-Martín M; Fox K; Cordon-Cardo C; Chang R; Sivendran S; Phelps RG; Saenger Y
    J Am Acad Dermatol; 2014 Jun; 70(6):1036-44. PubMed ID: 24698703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma.
    Francken AB; Accortt NA; Shaw HM; Wiener M; Soong SJ; Hoekstra HJ; Thompson JF
    Ann Surg Oncol; 2008 May; 15(5):1476-84. PubMed ID: 18196345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hazard-rate analysis and patterns of recurrence in early stage melanoma: moving towards a rationally designed surveillance strategy.
    Salama AK; de Rosa N; Scheri RP; Pruitt SK; Herndon JE; Marcello J; Tyler DS; Abernethy AP
    PLoS One; 2013; 8(3):e57665. PubMed ID: 23516415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late relapse from cutaneous stage I malignant melanoma.
    Shaw HM; Beattie CW; McCarthy WH; Milton GW
    Arch Surg; 1985 Oct; 120(10):1155-9. PubMed ID: 4038058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of first-recurrence and post-recurrence survival in patients with primary cutaneous melanoma after sentinel lymph node biopsy.
    Dalal KM; Patel A; Brady MS; Jaques DP; Coit DG
    Ann Surg Oncol; 2007 Jun; 14(6):1934-42. PubMed ID: 17406951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early time to recurrence predicts worse survival in patients with localized or regionally advanced cutaneous melanoma.
    Liang C; Hu W; Li J; Zhang X; Zhou Z; Liang Y
    Dermatol Ther; 2021 Jul; 34(4):e14981. PubMed ID: 33993602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.
    Eggermont AMM; Blank CU; Mandalà M; Long GV; Atkinson VG; Dalle S; Haydon AM; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; van Akkooi ACJ; Krepler C; Ibrahim N; Marreaud S; Kicinski M; Suciu S; Robert C;
    Lancet Oncol; 2021 May; 22(5):643-654. PubMed ID: 33857412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and Survival.
    Vallet A; Oriano B; Mortier L; Dalle S; Dutriaux C; Guillot B; Leccia MT; Dalac S; Saiag P; Lacour JP; Legoupil D; De Quatrebarbes J; Brunet-Possenti F; Lesimple T; Arnault JP; Aubin F; Granel-Brocard F; Stoebner PE; Maubec E; Dreno B; Allayous C; Porcher R; Lebbé C;
    JAMA Dermatol; 2019 Jun; 155(6):673-678. PubMed ID: 31042256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conditional Survival: An Assessment of the Prognosis of Patients at Time Points After Initial Diagnosis and Treatment of Locoregional Melanoma Metastasis.
    Haydu LE; Scolyer RA; Lo S; Quinn MJ; Saw RPM; Shannon KF; Spillane AJ; Stretch JR; McCarthy WH; Thompson JF
    J Clin Oncol; 2017 May; 35(15):1721-1729. PubMed ID: 28375785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultrasound-based follow-up does not increase survival in early-stage melanoma patients: A comparative cohort study.
    Ribero S; Podlipnik S; Osella-Abate S; Sportoletti-Baduel E; Manubens E; Barreiro A; Caliendo V; Chavez-Bourgeois M; Carrera C; Cassoni P; Malvehy J; Fierro MT; Puig S
    Eur J Cancer; 2017 Nov; 85():59-66. PubMed ID: 28888850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of Gene Expression Profile Tests for Prognosis in Patients With Localized Cutaneous Melanoma: A Systematic Review and Meta-analysis.
    Marchetti MA; Coit DG; Dusza SW; Yu A; McLean L; Hu Y; Nanda JK; Matsoukas K; Mancebo SE; Bartlett EK
    JAMA Dermatol; 2020 Sep; 156(9):953-962. PubMed ID: 32745161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma.
    Haydu LE; Lo SN; McQuade JL; Amaria RN; Wargo J; Ross MI; Cormier JN; Lucci A; Lee JE; Ferguson SD; Saw RPM; Spillane AJ; Shannon KF; Stretch JR; Hwu P; Patel SP; Diab A; Wong MKK; Glitza Oliva IC; Tawbi H; Carlino MS; Menzies AM; Long GV; Lazar AJ; Tetzlaff MT; Scolyer RA; Gershenwald JE; Thompson JF; Davies MA
    J Clin Oncol; 2020 May; 38(13):1429-1441. PubMed ID: 31990608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapse patterns in patients with local and regional cutaneous melanoma.
    Tas F; Erturk K
    Clin Transl Oncol; 2019 Apr; 21(4):412-419. PubMed ID: 30182208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Descriptive analysis of cutaneous recurrence patterns in patients with melanoma].
    Marcoval J; Ferreres JR; Penín RM; Piulats JM; Caminal JM; Fabra A
    Actas Dermosifiliogr; 2011 Dec; 102(10):791-6. PubMed ID: 21658662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of recurrence and retreatment outcomes among clinical stage I and II head and neck melanoma patients.
    Namin AW; Cornell GE; Thombs LA; Zitsch RP
    Head Neck; 2019 May; 41(5):1304-1311. PubMed ID: 30629324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.